Post Surgical Pain Drug Pipeline Analysis Report 2025
Description
Many people have post-surgical pain, which is brought on by tissue damage, inflammation, and nerve damage. Some individuals may experience acute discomfort, while others may develop chronic pain, depending on the nature and degree of the procedure. In addition to swelling, soreness, and restricted mobility, pain usually presents as aching, throbbing, or stabbing feelings. To reduce discomfort, avoid problems like infections, and encourage healing, proper treatment is essential. Effective post-surgical pain management frequently involves a mix of medication, physical therapy, and psychological support. Moreover, its rising prevalence is anticipated to positively impact the pipeline landscape for post surgical pain drugs.
Report Coverage
The Post Surgical Pain Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into post surgical pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for post surgical pain. The post surgical pain report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The post surgical pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with post surgical pain treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post surgical pain.
Post Surgical Pain Drug Pipeline Outlook
Post-operative discomfort is primarily caused by inflammation and tissue damage after surgery. Chemical mediators such as prostaglandins, bradykinin, and substance P are released by injured, strained, or cut tissues, and these mediators cause the affected area's nociceptors to become active. This sets off a series of impulses that are sent to the brain and spinal cord via peripheral nerves, causing pain perception. Furthermore, even after the injury heals, central sensitization may take place, which intensifies pain signals in the neurological system and causes increased sensitivity and ongoing suffering.
The most widely used medications for post-operative pain, particularly for mild to moderate pain are medications like acetaminophen. It functions by lowering inflammation, obstructing pain signals, and producing analgesia without the dangers of opioids. They are appropriate for controlling pain following surgery while lowering the risk of addiction or serious adverse effects since they are typically well-tolerated, effective, and long-lasting. Further, the rising focus on the development of post surgical pain emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Post Surgical Pain Epidemiology
According to studies, between 61% and 73% of patients report having moderate to severe pain during the first 48 hours following surgery. Furthermore, according to a systematic analysis, between 31% and 58% of people suffer moderate to severe pain after being released from the hospital, underscoring the continued difficulties in managing pain. Many patients continue to have insufficient pain management even after taking analgesics. In some studies, more than 80% of patients report inadequately managed postoperative pain.
Post Surgical Pain – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of post surgical pain drug candidates based on several segmentations including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials, with a substantial number of post surgical pain drugs undergoing clinical development.
Post Surgical Pain – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under post surgical pain pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The post surgical pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post surgical pain.
Post Surgical Pain Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the post surgical pain drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed post surgical pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in post surgical pain clinical trials:
Major drugs currently in the drug pipeline are as follows:
Qutenza
Sponsored by Averitas Pharma, Inc., the QUTENZA (capsaicin) 8% topical system is part of a multicenter clinical trial to investigate the efficacy and safety of post-surgical neuropathic pain (PSNP). The study is under Phase III clinical development.
Drug: F14
Arthritis Innovation Corporation is conducting a study aimed at examining the efficacy of the investigational drug F14 for the treatment of post surgical pain. The study is under Phase III clinical development.
Reasons To Buy This Report
The Post Surgical Pain Drug Report provides a strategic overview of the latest and future landscape of treatments for post surgical pain. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within post surgical pain pipeline insights.
Key Questions Answered in the Post Surgical Pain – Pipeline Insight Report
Global Cancer Therapeutics Market
Global Clinical Trials Market
Report Coverage
The Post Surgical Pain Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into post surgical pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for post surgical pain. The post surgical pain report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The post surgical pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with post surgical pain treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post surgical pain.
Post Surgical Pain Drug Pipeline Outlook
Post-operative discomfort is primarily caused by inflammation and tissue damage after surgery. Chemical mediators such as prostaglandins, bradykinin, and substance P are released by injured, strained, or cut tissues, and these mediators cause the affected area's nociceptors to become active. This sets off a series of impulses that are sent to the brain and spinal cord via peripheral nerves, causing pain perception. Furthermore, even after the injury heals, central sensitization may take place, which intensifies pain signals in the neurological system and causes increased sensitivity and ongoing suffering.
The most widely used medications for post-operative pain, particularly for mild to moderate pain are medications like acetaminophen. It functions by lowering inflammation, obstructing pain signals, and producing analgesia without the dangers of opioids. They are appropriate for controlling pain following surgery while lowering the risk of addiction or serious adverse effects since they are typically well-tolerated, effective, and long-lasting. Further, the rising focus on the development of post surgical pain emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Post Surgical Pain Epidemiology
According to studies, between 61% and 73% of patients report having moderate to severe pain during the first 48 hours following surgery. Furthermore, according to a systematic analysis, between 31% and 58% of people suffer moderate to severe pain after being released from the hospital, underscoring the continued difficulties in managing pain. Many patients continue to have insufficient pain management even after taking analgesics. In some studies, more than 80% of patients report inadequately managed postoperative pain.
Post Surgical Pain – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of post surgical pain drug candidates based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibody
- Polymers
- Peptides
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials, with a substantial number of post surgical pain drugs undergoing clinical development.
Post Surgical Pain – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under post surgical pain pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The post surgical pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post surgical pain.
Post Surgical Pain Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the post surgical pain drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed post surgical pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in post surgical pain clinical trials:
- Averitas Pharma, Inc.
- Arthritis Innovation Corporation
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Avenue Therapeutics, Inc.
- Neuros Medical, Inc.
- Heron Therapeutics
- Angiodynamics, Inc.
Major drugs currently in the drug pipeline are as follows:
Qutenza
Sponsored by Averitas Pharma, Inc., the QUTENZA (capsaicin) 8% topical system is part of a multicenter clinical trial to investigate the efficacy and safety of post-surgical neuropathic pain (PSNP). The study is under Phase III clinical development.
Drug: F14
Arthritis Innovation Corporation is conducting a study aimed at examining the efficacy of the investigational drug F14 for the treatment of post surgical pain. The study is under Phase III clinical development.
Reasons To Buy This Report
The Post Surgical Pain Drug Report provides a strategic overview of the latest and future landscape of treatments for post surgical pain. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within post surgical pain pipeline insights.
Key Questions Answered in the Post Surgical Pain – Pipeline Insight Report
- What is the current landscape of post surgical pain pipeline drugs?
- Which companies/institutions are developing post surgical pain emerging drugs?
- How many phase II drugs are currently present in post surgical pain pipeline drugs?
- Which company is leading the post surgical pain pipeline development activities?
- What is the current post surgical pain therapeutic assessment?
- What are the opportunities and challenges present in the post surgical pain drug pipeline landscape?
- What is the efficacy and safety profile of post surgical pain pipeline drugs?
- Which companies/institutions are involved in post surgical pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in post surgical pain?
Global Cancer Therapeutics Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Post Surgical Pain
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Post Surgical Pain
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Post Surgical Pain
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Post Surgical Pain: Epidemiology Snapshot
- 5.1 Post Surgical Pain Incidence by Key Markets
- 5.2 Post Surgical Pain – Patients Seeking Treatment in Key Markets
- 6 Post Surgical Pain: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Post Surgical Pain: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Post Surgical Pain, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Post Surgical Pain Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Post Surgical Pain Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Qutenza
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drugs: F14
- 10.2.3 Other Drugs
- 11 Post Surgical Pain Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: YZJ-4729
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: HR18034
- 11.2.3 Other Drugs
- 12 Post Surgical Pain, Key Drug Pipeline Companies
- 12.1 Averitas Pharma, Inc.
- 12.1.1 Company Snapshot
- 12.1.2 Pipeline Product Portfolio
- 12.1.3 Financial Analysis
- 12.1.4 Recent News and Developments
- 12.2 Arthritis Innovation Corporation
- 12.2.1 Company Snapshot
- 12.2.2 Pipeline Product Portfolio
- 12.2.3 Financial Analysis
- 12.2.4 Recent News and Developments
- 12.3 Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- 12.3.1 Company Snapshot
- 12.3.2 Pipeline Product Portfolio
- 12.3.3 Financial Analysis
- 12.3.4 Recent News and Developments
- 12.4 Angiodynamics, Inc.
- 12.4.1 Company Snapshot
- 12.4.2 Pipeline Product Portfolio
- 12.4.3 Financial Analysis
- 12.4.4 Recent News and Developments
- 12.5 Avenue Therapeutics, Inc.
- 12.5.1 Company Snapshot
- 12.5.2 Pipeline Product Portfolio
- 12.5.3 Financial Analysis
- 12.5.4 Recent News and Developments
- 12.6 Neuros Medical, Inc.
- 12.6.1 Company Snapshot
- 12.6.2 Pipeline Product Portfolio
- 12.6.3 Financial Analysis
- 12.6.4 Recent News and Developments
- 12.7 Shanghai Hengrui Pharmaceutical Co., Ltd.
- 12.7.1 Company Snapshot
- 12.7.2 Pipeline Product Portfolio
- 12.7.3 Financial Analysis
- 12.7.4 Recent News and Developments
- 12.8 Heron Therapeutics
- 12.8.1 Company Snapshot
- 12.8.2 Pipeline Product Portfolio
- 12.8.3 Financial Analysis
- 12.8.4 Recent News and Developments
- 13 Regulatory Framework for Drug Approval, By Region
- 14 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
